surufatinib + serplulimab + albumin-paclitaxel + gemcitabine

This is a four-drug combination regimen consisting of surufatinib, serplulimab, albumin-bound paclitaxel (nab-paclitaxel), and gemcitabine. - **Surufatinib** is an oral small molecule inhibitor targeting multiple receptor tyrosine kinases involved in tumor angiogenesis and immune modulation, including vascular endothelial growth factor receptors (VEGFR1/2/3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF1R). - **Serplulimab** is a fully human monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immunity. - **Albumin-paclitaxel** (nab-paclitaxel) is a nanoparticle albumin-bound formulation of the microtubule inhibitor paclitaxel, designed to improve delivery and reduce toxicity compared to conventional paclitaxel. - **Gemcitabine** is a nucleoside analog used as chemotherapy that inhibits DNA synthesis in rapidly dividing cells. This combination brings together targeted therapy, immunotherapy, and cytotoxic chemotherapy for potential synergistic anti-tumor effects. Nab-paclitaxel plus gemcitabine is an established regimen for pancreatic cancer[1][2][4], while surufatinib and serplulimab are investigational agents with activity in solid tumors.